News & Views
News & Views
Iksuda presents encouraging IKS014 Phase 1 data at ESMO
New safety, efficacy and pharmacokinetic results presented from dose escalation portion of the study Anti-tumour activity observed across all dose levels and in various tumour indications
Iksuda presents encouraging IKS014 Phase 1 data at ESMO
New safety, efficacy and pharmacokinetic results presented from dose escalation portion of the study Anti-tumour activity observed across all dose levels and in various tumour indications
Iksuda to present IKS014 Phase 1 data at ESMO
Newcastle, UK, 14 October 2025: Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs), will present new data from its Phase 1 study of IKS014, a human epidermal growth factor receptor 2 (HER2) ADC, in patients with advanced HER2+ solid tumours, at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany (17-21 October).
Iksuda Therapeutics receives FDA IND clearance for IKS014
FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore. Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical activity across multiple tumour types
Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas
First-in-human trial is designed to determine recommended dose of IKS03, a CD19-directed antibody drug conjugate, for the subsequent dose-expansion. IKS03 is Iksuda’s second asset to begin clinical testing.
Iksuda to present growing ADC pipeline at AACR
Introduces the ProAlk payload series to address the growing challenge of ADC sequencing
Iksuda abstracts at AACR 2025
Iksuda’s abstracts have been scheduled for presentation in a Poster Session at the AACR Annual Meeting 2025 in Chicago, on Monday April 28 and have been published to the AACR Online Program Planner.